Modern practice of lipid-lowering pharmacotherapy: the choice of the optimal fixed combination

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cardiovascular diseases (CVD) of atherosclerotic genesis still remain the leading cause of death and disability among the population of many countries of the world. The key to reducing the risk of developing cardiovascular complications and adverse outcomes in patients with CVD is the control of cardiovascular risk factors. The article discusses the prevalence and significance of CVD risk factors. A significant increase in the prevalence of such CVD risk factors as type 2 diabetes and overweight/obesity is emphasized. In real clinical practice, doctors are faced with various disorders of lipid metabolism. Dyslipidemia is recognized as a leading risk factor for atherosclerosis. Therapeutic targets of lipid-lowering therapy, optimal values of lipid parameters depending on the risk category, issues of lipid-lowering therapy are discussed. The mechanisms of action of statins and fibrates have been disclosed. The strategy of combined lipid-lowering therapy is considered as a way to reduce residual risk. Simplification of therapeutic regimens using a fixed combination of rosuvastatin and fenofibrate increases patient adherence to treatment and its outcome.

Full Text

Restricted Access

About the authors

Elena V. Biryukova

A.I. Yevdokimov Moscow State University of Medicine and Dentistry; Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department

Author for correspondence.
Email: lena@obsudim.ru
ORCID iD: 0000-0001-9007-4123

Dr. Sci.(Med.), Professor at the Department of Endocrinology and Diabetology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Russian Federation, Moscow; Moscow

M. V. Shinkin

Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department

Email: lena@obsudim.ru
ORCID iD: 0000-0003-1548-1487
Russian Federation, Moscow

I. A. Morozova

Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department

Email: lena@obsudim.ru
ORCID iD: 0000-0002-1939-261X
Russian Federation, Moscow

References

  1. Liu T., Zhao D., Qi Y. Global Trends in the Epidemiology and Management of Dyslipidemia. J Clin Med. 2022;1, 6377. doi: 10.3390/jcm11216377.
  2. Virani S.S., Alonso A., Benjamin E.J., Bittencourt M.S., et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141(9);e139-e596. doi: 10.1161/CIR.0000000000000757.
  3. Kumar A., Siddharth V., Singh S.I., Narang R. Cost analysis of treating cardiovascular diseases in a super-specialty hospital. PLoS ONE 2022; 17(1):e0262190. doi: 10.1371/journal.pone.0262190.
  4. Сердечно-сосудистые заболевания. [Cardiovascular diseases. (In Russ.)].URL: https://www.who.int/ru/health-topics/cardiovascular-diseases#tab=tab_1
  5. Kotseva K., De Backer G., De Bacquer D., et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021; 28(4):370–79. doi: 10.1177/2047487320908698.
  6. Шляхто Е.В., Звартау Н. Э., Виллевальде С.В. и др. Система управления сердечно-сосудистыми рисками: предпосылки к созданию, принципы организации, таргетные группы. Российский кардиологический журнал. 2019;24(11):69–82. [Shlyakhto E.V., Zvartau N.E., Villeval’de S.V. et al. Cardiovascular risk management system: prerequisites for creation, principles of organization, target groups. Rossiiskii kardiologicheskii zhurnal. 2019;24(11):69–82. (In Russ.)]. doi: 10.15829/1560-4071-2019-11-69-82.
  7. Tiffe T., Wagner M., Rucker V., et al. Control of cardiovascular risk factors and its determinants in the general population – findings from the STAAB cohort study. BMC Cardiovasc Disord. 2017;17(1):276. doi: 10.1186/s12872-017-0708-x.
  8. Погосова Н.В., Оганов Р.Г., Бойцов С.А. и др. Анализ ключевых показателей вторичной профилактики у пациентов с ишемической болезнью сердца в России и Европе по результатам российской части международного многоцентрового исследования EUROASPIRE V. Кардиоваскулярная терапия и профилактика. 2020;19(6):2739. [Pogosova N.V., Oganov R.G., Boitsov S.A. et al. Analysis of key indicators of secondary prevention in patients with coronary heart disease in Russia and Europe based on the results of the Russian part of the international multicenter study EUROASPIRE V. Kardiovaskulyarnaya terapiya i profilaktika. 2020;19(6):2739. (In Russ.)]. doi: 10.15829/1728-8800-2020-2739.
  9. Арутюнов Г.П., Бойцов С.А., Воевода М.И. и др. Коррекция гипертриглицеридемии с целью снижения остаточного риска при заболеваниях, вызванных атеросклерозом. Заключение Совета экспертов. Российский кардиологический журнал. 2019;24(9):44–51. [Arutyunov G.P., Boitsov S.A., Voevoda M.I. et al. Correction of hypertriglyceridemia to reduce residual risk in diseases caused by atherosclerosis. Conclusion of the Council of Experts. Rossiiskii kardiologicheskii zhurnal. 2019;24(9):44–51. (In Russ.)]. doi: 10.15829/1560-4071- 2019-9-44-51.
  10. Boren J., Chapman M.J., Krauss R.M., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313–30. doi: 10.1093/eurheartj/ehz962.
  11. Pirillo A., Casula M., Olmastroni E., et al. Global epidemiology of dyslipidaemias. Nature Rev Cardiol. 2021;18:689–700. doi: 10.1038/s41569-021-00541-4.
  12. Сергиенко И.В., Аншелес А.А. Патогенез, диагностика и лечение атеросклероза: практические аспекты. Кардиологический вестник. 2021;16(1):64–72. [Sergienko I.V., Ansheles A.A. Pathogenesis, diagnosis and treatment of atherosclerosis: practical aspects. Kardiologicheskii vestnik. 2021;16(1):64–72. (In Russ.)]. doi: 10.17116/Cardiobulletin20211601164.
  13. Martone A.M., Landi F., Petricca L., et al. Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project. European Journal of Public Health, Volume 32, Issue 3, June 2022, Pages 402–407, doi: 10.1093/eurpub/ckab224
  14. Ormazaba V., Nair S., Elfeky O., Aguayo C., Salomon C., et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:122. Published online 2018 Aug 31. doi: 10.1186/s12933-018-0762-4.
  15. Атеросклероз и дислипидемии. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7–42. [Atherosclerosis and dyslipidemia. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Ateroskleroz i dislipidemii. 2020;1(38):7–42. (In Russ.)]. doi: 10.34687/2219–8202.JAD.2020.01.0002.
  16. Карпов Ю.А. Роль статинотерапии в профилактике сердечно-сосудистых заболеваний в реальной клинической практике. Доктор.Ру. 2021;20(11):17–27. [Karpov Yu.A. The role of statin therapy in the prevention of cardiovascular diseases in real clinical practice. Doctor.Ru. 2021;20(11):17–27. (In Russ.)]. doi: 10.31550/1727-2378-2021-20-11-17-27.
  17. Yoo H.J., Choi K.M. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes. 2014;5:357–63. doi: 10.4239/wjd.v5.i3.357.
  18. Lim P., Bleich D. Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia. Int J Cardiol Cardiovas Risk Prev. 2022;14 200141. doi: 10.1016/j.ijcrp.2022.200141.
  19. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. М., 2021. [Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 10th edition. M., 2021. (In Russ.)].
  20. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–12. [Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes in the adult population of Russia (NATION study). Sakharnyi diabet. 2016;19(2):104–12. (In Russ.)]. doi: 10.14341/DM2004116-17.
  21. Poznyak A., Grechko A.V., Poggio P., et al. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21(5):1835. doi: 10.3390/ijms21051835.
  22. Morrish N.J., Wang S.L., Stevens L.K., et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S14–S21. doi: 10.1007/pl00002934.
  23. Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J. Atheroscler. Thromb. 2018;25:27–39. doi: 10.5551/jat.RV17014.
  24. Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771–82. doi: 10.5551/jat.RV17023.
  25. Duncan M.S., Vasan R.S., Xanthakis V. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years. J Am Heart Assoc. 2019;8(11):e011433. doi: 10.1161/JAHA.118.011433.
  26. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;9607(371):117–25. doi: 10.1016/S0140-6736(08)60104-X.
  27. Toth P.P. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171–83. doi: 10.2147/VHRM.S104369.
  28. Hokanson J.E. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep. 2002;4(6):488–93. doi: 10.1007/s11886-002-0112-7.
  29. Holmes M.V., Asselbergs F.W., Palmer T.M., et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50. doi: 10.1093/eurheartj/eht571.
  30. Сусеков А.В. Клинические исследования с розувастатином из проекта GALAXY в контексте новых рекомендаций EAS/ESC-2016 по дислипидемиям. Часть 1. Consilium Medicum. 2017;19 (12):12–9. [Susekov A.V. Clinical trials with rosuvastatin from the GALAXY project in the context of the new EAS/ESC-2016 guidelines on dyslipidaemias. Part 1. Consilium Medicum. 2017;19(12):12–9. (In Russ.)]. doi: 10.26442/2075-1753_19.12.12-19.
  31. Данилов А.И., Козлов С.Н., Евсеев А.В. Статины как компонент гиполипидемической терапии. Обзоры поклинической фармакологии и лекарственной терапии. 2019;17(4):79–82. [Danilov A.I., Kozlov S.N., Evseev A.V. Statins as a component of lipid-lowering therapy. Obzory poklinicheskoi farmakologii i lekarstvennoi terapii. 2019;17(4):79–82. (In Russ.)]. doi: 10.7816/RCF17479-82.
  32. Арутюнов А.Г., Арутюнов Г.П. Коррекция статинами сердечно-сосудистого риска. Проблемы и нерешенные вопросы на современном этапе. Сердце: журнал для практикующих врачей. 2015;14(4):193–212. [Arutyunov A.G., Arutyunov G.P. Adjustment of cardiovascular risk with statins. Problems and unresolved issues at the present stage. Serdtse: zhurnal dlya praktikuyushchikh vrachei. 2015;14(4):193–212. (In Russ.)]. Doi: 10.18087/ rhj.2015.4.2093.
  33. Koskinas K.C., Siontis G.CM, Piccolo R., et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39:1172–180. doi: 10.1093/eurheartj/ehx566.
  34. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013. doi: 10.1002/14651858.cd004816.pub5.
  35. Huff M.W., Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol. 1997;8:138–45. doi: 10.1097/00041433-199706000-00003.
  36. Stancu C., Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87. doi: 10.1111/j.1582-4934.2001.tb00172.x.
  37. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160–64. doi: 10.1126/science.1059344.
  38. Zhang Q., Dong J., Ze Yu. Pleiotropic use of Statins as non-lipid-lowering drugs. Int J Biol Sci. 2020; 16(14): 2704–11. doi: 10.7150/ijbs.42965.
  39. Бубнова М.Г., Ильченко М.Ю., Лебедев П.А. Статины в первичной профилактике сердечно-сосудистых заболеваний. Возможности розувастатина. CardioСоматика. 2021;12(2):110–18. [Bubnova M.G., Il’chenko M.Yu., Lebedev P.A. Statins in the primary prevention of cardiovascular disease. Possibilities of rosuvastatin. CardioSomatika. 2021;12(2):110–18. (In Russ.)]. doi: 10.26442/22217185.2021. 2.200859.
  40. Luvai A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. Clin Med Insights Cardiol. 2012;6:17–33. doi: 10.4137/CMC.S4324.
  41. Остроумова О.Д., Кочетков А.И., Листратов А.И. Комбинированная гиполипидемическая терапия с позиций современных рекомендаций по лечению дислипидемии. Медицинский алфавит. 2021;17:13–9. [Ostroumova O.D., Kochetkov A.I., Listratov A.I. Combined lipid-lowering therapy from the standpoint of current recommendations for the treatment of dyslipidemia. Meditsinskii alfavit. 2021;17:13–9. (In Russ.)]. doi: 10.33667/2078-5631-2021-17-13-19.
  42. McKenney J.M., Jones P.H., Adamczyk M.A., et al. Comparison of efficacy of rosuvastatin verus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689–98. doi: 10.1185/030079903125002405.
  43. Karlson B.W., Wiklund O., Palmer M.K., et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212–17. doi: 10.1093/ehjcvp/pvw006.
  44. Blasetto J.W, Stein E.A., Brown W.V., et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups Am J Cardiol. 2003;91(5A):3C–10C. doi: 10.1016/S0002-9149(03)00003-1.
  45. Обрезан А.Г., Ежов М.В., Cергиенко И.В. и др. Место фиксированной комбинации розувастатина и фенофибрата в лечении пациентов с комбинированной атерогенной дислипидемией. Атеросклероз и дислипидемии. 2022;1(46):5–16. [Obrezan A.G., Ezhov M.V., Cergienko I.V. et al. Place of the fixed combination of rosuvastatin and fenofibrate in the treatment of patients with combined atherogenic dyslipidemia. Ateroskleroz i dislipidemii. 2022;1(46):5–16. (In Russ.)]. doi: 10.34687/2219-8202.JAD.2022.01.0001.
  46. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–82. doi: 10.1016/S0140-6736(09)60447-5.
  47. Nichols G.A., Pharm S.F.D., Reynolds K., et al. “Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21(2):366–71. doi: 10.1111/dom.13537.
  48. Mijares A.H., Ascaso J.F., Blasco M., et al. “Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects”. Clin Investig Arterioscler. 2019;31(2):75–88. doi: 10.1016/j.arteri.2018.06.007.
  49. Уткина Е.А., Афанасьева О.И., Покровский С.Н. Гетерогенность липопротеидов и их роль в развитии сердечно-сосудистых заболеваний. Российский кардиологический журнал. 2019;24(5):82–9. [Utkina E.A., Afanas’eva O.I., Pokrovskii S.N. Heterogeneity of lipoproteins and their role in the development of cardiovascular diseases. Rossiiskii kardiologicheskii zhurnal. 2019;24(5):82–9. (In Russ.)]. doi: 10.15829/1560-4071-2019-5-82-89.
  50. Зубарева М.Ю., Рожкова Т.А., Горнякова Н.Б. и др. Резидуальный (остаточный) риск у больных очень высокого риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование «Кристалл». Часть 1: цель, задачи, дизайн и исходные характеристики включенных пациентов. Атеросклероз и дислипидемии 2013;1(10):26–34. [Zubareva M.Yu., Rozhkova T.A., Gornyakova N.B. et al. Residual (residual) risk in very high-risk patients with atherogenic dyslipidaemias on statin therapy. Prospective study «Crystal». Part 1: Purpose, objectives, design, and baseline characteristics of the included patients. Ateroskleroz i dislipidemii 2013;1(10):26–34. (In Russ.)].
  51. Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992;70(19):H3–H9. doi: 10.1016/0002-9149(92)91083-g.
  52. Halcox J.P., Banegas J.R., Roy C., et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160. doi: 10.1186/s12872–017–0591–5.
  53. Boren J., Williams K.J. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473–83. doi: 10.1097/MOL.0000000000000330.
  54. Хазова Е.В., Булашова О.В. Остаточный риск у пациентов с атеросклеротическими кардиоваскулярными заболеваниями. Кардиоваскулярная терапия и профилактика. 2023;22(1):3382. [Khazova E.V., Bulashova O.V. Residual risk in patients with atherosclerotic cardiovascular disease. Kardiovaskulyarnaya terapiya i profilaktika. 2023;22(1):3382. (In Russ.)]. doi: 10.15829/1728-8800-2023-3382.
  55. Elam M.B., Ginsberg H.N., Lovato L.C., et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370–80. doi: 10.1001/ja-macardio.2016.4828.
  56. Гусенбекова Д.Г., Аметов А.С. Эффективность комбинированной гиполипидемической терапии у больных с нарушениями углеводного обмена. Эндокринология: новости, мнения, обучение. 2021;10(3):46–51. doi: 10.33029/2304-9529-2021-10-3-46-51. [Gusenbekova D.G., Ametov A.S. The effectiveness of combined lipid-lowering therapy in patients with impaired carbohydrate metabolism. Endokrinologiya: novosti, mneniya, obuchenie. 2021;10(3):46–51. (In Russ.)].
  57. Ширинский И.В., Ширинский В.С. Плейотропные свойства PPARα: от экспериментов к клинике. Медицинская Иммунология. 2021;21(3):439–54. [Shirinskii I.V., Shirinskii V.S. Pleiotropic properties of PPARα: from experiments to the clinic. Meditsinskaya Immunologiya. 2021;21(3):439–54. (In Russ.)].
  58. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121–53. doi: 10.2165/00003495-200767010-00013.
  59. Mahmoud A., Jamialahmadi T., Johnston T.P., Sahebkar A. Impact of fenofibrate on NAFLD/NASH: A genetic perspective. Drug Discov Today. 2022;27(8):2363–72. doi: 10.1016/j.drudis.2022.05.007.
  60. Kim N.H., Han K.H., Choi J., et al. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019;366:l5125. doi: 10.1136/bmj.l512.
  61. Keech A., Simes R.J., Barter P., et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. doi: 10.1016/S0140–6736(05)67667–2.
  62. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905–10. doi: 10.1016/S0140-6736(00)04209-4.
  63. Государственный реестр лекарственных средств Минздрава России. [State Register of Medicines of the Ministry of Health of Russia. (In Russ.)]. URL: http://grls.rosminzdrav.ru
  64. Tiwari A., Biswas K., Jadhav P., et al. Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review. J Curr Med Res Opin. 2021;04(03):867–77 doi: 10.15520/jcmro.v4i03.405.
  65. Barkate H., Patel P., Shah D., Vyas F. Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population. Indian J Endocrinol Metab. 2018;22(5):627–31. doi: 10.4103/ijem.IJEM_321_16.
  66. Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Дислипидемии, атеросклероз и ишемическая болезнь сердца: генетика, патогенез, фенотипы, диагностика, терапия, коморбидность. Москва: ООО «ПатиСС», 2020. 295 с. [Sergienko I.V., Ansheles A.A., Kukharchuk V.V. Dyslipidemia, atherosclerosis and coronary heart disease: genetics, pathogenesis, phenotypes, diagnosis, therapy, comorbidity. Moscow: PatiSS, 2020. 295 p. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Lipid-lowering effectiveness of different satins

Download (137KB)
Indexing metadata
3. Fig. 2. Fenofibrate Treatment Slows the Progression of Coronary Atherosclerosis

Download (116KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies